Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Rare disease-focused Amicus Therapeutics is shelling out $100 million up front, and up to $350 million more in milestones, for the privately held gene therapy developer Celenex. The acquisition gives Amicus the rights to 10 gene therapy programs that were originally developed at the Center for Gene Therapy at Nationwide Children’s Hospital and Ohio State University. The three most advanced gene therapies each address a subtype of a rare, deadly, inherited nervous system disorder called Batten disease. The deal marks Amicus’s entry into gene therapy.
This article has been sent to the following recipient: